CALGB40503_2B: CALGB40503, figure 2B

CALGB40503_2BR Documentation

CALGB40503, figure 2B

Description

Kaplan-Meier digitized data from CALGB40503, figure 2B (PMID 27138575). A reported sample size of 350 for a primary endpoint of PFS in breast cancer.

Usage

CALGB40503_2B

Format

A data frame of 343 observations and 3 variables:

time event time (in months)
event OS event indicator (0: no event, 1: event)
arm treatment arms (l, l_b)

Source

Dickler MN, Barry WT, Cirrincione CT, et al. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol 2016; 34: 2602–9.

Examples

summary(CALGB40503_2B)

kmplot(CALGB40503_2B)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.